Search
forLearn 1 of 2
All learn results →Research 10 of 19
- Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Next Generation Therapeutics for Androgenetic Alopecia
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
- Topical solutions for androgenetic alopecia: evaluating efficacy and safety
Community 10 of 105
- Been off Tressless for a few years - what’s the latest on GT20029?
- GT20029 Will Replace Finasteride For Hair Loss
- Gt20026 - the actual cure to hairloss?
- GT20029: How It Works for Hair Loss - Hair Loss “Cure”
- Anyone immediately lose hope for gt20029 when they realised it’s developed by kintor
- GT20029 Big Phase 2 Update Results!
- GT20029 Phase 2 results are out
- Where are we with GT20029 ? Realistic Timeline ?
- When will GT20029 phase 3 trial begin?
- Won’t pp405 and gt20029 be patented and be almost unreasonably expensive